首页> Cancer immunology research> Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Myriam,Ben Khelil

第一单位： Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.

作者： Myriam,Ben Khelil ^[1] ; Maxime,Fredon ^[1] ; Nawfel,Adib ^[1] ; Adeline,Bouard ^[2] ; Marie,Perchaud ^[1] ; Syrine,Abdeljaoued ^[1] ; Charles-Frédéric,Mantion ^[1] ; Kamal,Asgarov ^[3] ; Philippe,Guillaume ^[4] ; Laurie,Spehner ^[1] ; Evan,Seffar ^[1] ; Marjorie,Labesse ^[1] ; Angélique,Vienot ^[5] ; Virginie,Mougey ^[2] ; Mathieu,Gonçalves-Venturelli ^[6] ; Sara,Bobisse ^[4] ; Alexandre,Harari ^[4] ; Camilla,Jandus ^[7] ; Francine,Garnache-Ottou ^[1] ; Delphine,Binda ^[8] ; Olivier,Adotévi ^[5] ; Yann,Godet ^[1] ; Marie,Kroemer ^[9] ; Christophe,Borg ^[5] ; Romain,Loyon ^[1]

作者单位： Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France. ^[1] Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.;ITAC Platform, University of Bourgogne Franche-Comté, Besançon, France. ^[2] Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.;ITAC Platform, University of Bourgogne Franche-Comté, Besançon, France.;INSERM CIC-1431, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Besançon, France. ^[3] Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.;Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland. ^[4] Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.;Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France. ^[5] Lymphobank SAS, Besançon, France. ^[6] Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.;Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. ^[7] INSERM CIC-1431, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Besançon, France. ^[8] Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.;Department of Pharmacy, University Hospital of Besançon, Besançon, France. ^[9]

医学主题词人类(Humans);动物(Animals);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);小鼠(Mice);转录因子(Transcription Factors);细胞系, 肿瘤(Cell Line, Tumor);免疫疗法(Immunotherapy);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);肿瘤(Neoplasms);疾病模型, 动物(Disease Models, Animal);女(雌)性(Female);组织相容性抗原Ⅰ类(Histocompatibility Antigens Class I)

DOI 10.1158/2326-6066.CIR-24-0207

PMID 41114529

发布时间 2026-01-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer immunology research

2026年14卷1期

139-154页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer immunology research

2026年14卷1期

139-154页

检索历史清除

Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

Cancer immunology research

相似文献

同项目论文

Cancer immunology research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

Cancer immunology research

相似文献

同项目论文

Cancer immunology research

相关期刊

检索历史清除